Lead Investigator: Sameer Jauhar, King’s College London
Title of Proposal Research: Conducting a systematic review and meta-analysis to assess the incidence and severity of withdrawal symptoms following discontinuation of antidepressants
Vivli Data Request: 9813
Funding Source: None
Potential Conflicts of Interest: Sameer Jauhar has received honoraria for educational talks given for Lundbeck, Sunovian and Janssen, on antipsychotics. This research is not being funded by any companies or organisations. Any conflicts of interests will be declared in the paper publication.
Summary of the Proposed Research:
This study will be a systematic review (a rigorous review of existing studies) and meta-analysis, where the results of the studies found in the systematic review are examined and their findings summarised.
This systematic review aims to explore discontinuation symptoms (e.g., physical and psychological symptoms attributed to the withdrawal of medication) after discontinuation of antidepressant medications (i.e., medications prescribed to treat mainly symptoms of anxiety and depression). Antidepressants are commonly used for a range of conditons. However, the topic of antidepressant withdrawal remains controversial and more research is needed to explore this. Although there is a large number of studies assessing antidepressant withdrawal, existing systematic reviews include a limited number of studies or survey data. This research will help us understand whether antidepressants can cause withdrawal reactions. It is also important to explore not only the prevalence of withdrawal symptoms for different antidepressant medications, but also assess the duration and severity of these symptoms. Findings from this research will be used to inform patient decisions and clinical guidelines regarding antidepressants.
Requested Studies:
Lader M, Stender K, Bürger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004;19(4):241-8. doi: 10.1002/da.20014
Data Contributor: Lundbeck
Study ID: false
Data Request ID: 00009813
Sponsor ID: Lader et al 2004
Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry. 2006 Sep;189:264-72. doi: 10.1192/bjp.bp.105.012799
Data Contributor: Lundbeck
Study ID: false
Data Request ID: 00009813
Sponsor ID: Baldwin et al 2006
A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Lu AA21004 (15 and 20 mg/Day) in the Acute Treatment of Adult Patients With Major Depressive Disorder
Data Contributor: Lundbeck
Study ID: NCT01140906
Sponsor ID: 13267A
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT01163266
Sponsor ID: LuAA21004_316
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT01153009
Sponsor ID: LuAA21004_315
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
Data Contributor: Pfizer Inc.
Study ID: NCT00300378
Sponsor ID: 3151A1-333
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
Data Contributor: Pfizer Inc.
Study ID: NCT00277823
Sponsor ID: 3151A1-332
Fluoxetine Versus Paroxetine in Depression: Comparison of Discontinuation-Emergent Signs and Symptoms
Data Contributor: Lilly
Study ID: B1Y-MC-HCJF
Sponsor ID: B1Y-MC-HCJF
Fluoxetine Versus Sertaline and Paroxetine in Major Depression: Comparison of Discontinuation-Emergetn Signs and Symptoms
Data Contributor: Lilly
Study ID: B1Y-MC-HCIT
Sponsor ID: B1Y-MC-HCIT
Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol. 2006 May;21(3):159-69. doi: 10.1097/01.yic.0000194377.88330.1d. Study 95505
Data Contributor: Lundbeck
Study ID: false
Sponsor ID: Baldwin et al 2006
Montgomery SA, Nil R, Dürr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry. 2005 Oct;66(10):1270-8. doi: 10.4088/jcp.v66n1009. Study 99269.
Data Contributor: Lundbeck
Study ID: false
Sponsor ID: Montgomery et al 2005